IBD is an inflammatory disorder of the colon and small intestine. The pathogenesis of IBD is correlated with alterations in the immunological mechanisms involved in the resolution of inflammation resulting in excessive and persistent inflammation. More recently, specific mechanisms involved in the resolution of inflammation have been identified with macrophages playing a key part in preventing an excessive immune response. Intestinal macrophages are considered to be the main players in establishing and maintaining gut homeostasis. Deregulation of intestinal macrophages, therefore, results in a loss of tolerance towards commensal bacteria and food antigens, which is believed to underlie the chronic inflammation observed in IBD.
Factors | Impact on Macrophage Phenotype |
---|---|
Cytokine Milieu |
The cytokine-rich environment of the inflamed gut skews macrophage polarization.
|
Hypoxia | Hypoxia-inducible factors (HIFs) modulate macrophage metabolism and function, favoring a pro-inflammatory phenotype under certain conditions. |
Dietary and Microbial Metabolites |
|
Extracellular Matrix Components | Changes in the extracellular matrix, such as increased deposition of fibronectin or hyaluronan during inflammation, provide signals that can exacerbate M1 polarization and perpetuate inflammation. |
In IBD, an imbalance between M1 and M2 macrophages is frequently observed, and overexpression of M1 macrophages exacerbates disease pathology. The intestinal microenvironment has a profound effect on macrophage behavior, shaping macrophage phenotype and function through a range of signals from the extracellular matrix, stromal cells, cytokines, and metabolites. Key factors include:
Macrophages do not act in isolation. Their interactions with intestinal epithelial cells and the gut microbiota are central to maintaining intestinal homeostasis and mediating inflammatory responses in IBD.
Macrophage-Epithelial Cell Interactions
Macrophage-Microbiota Interactions
Tumor Necrosis Factor-Alpha (TNF-α)
Interleukin-1 Beta (IL-1β)
Interleukin-6 (IL-6)
Macrophages exhibit defective efferocytosis in IBD, resulting in the accumulation of apoptotic epithelial cells. This unregulated cell death fosters breaches in the barrier and exposes underlying tissues to luminal antigens.
Increased epithelial permeability allows the translocation of microbial products, such as lipopolysaccharides (LPS), into the lamina propria. These products engage macrophage Toll-like receptors (TLRs), perpetuating a vicious cycle of immune activation and tissue injury.
The pathogenesis of IBD is multifactorial, involving genetic, environmental, microbial, and immunological contributors. Among these, macrophages have emerged as pivotal players in driving intestinal inflammation, presenting a unique therapeutic target for addressing the complex mechanisms underlying IBD.
Strategies | Specific Programs |
---|---|
Modulating Macrophage Polarization |
|
Targeting Macrophage Recruitment and Trafficking |
|
Macrophage-specific Nanomedicine |
|
Inhibiting Macrophage Cytokine Production |
|
Enhancing Macrophage-mediated Resolution of Inflammation |
|
Based on a powerful macrophage therapeutics development platform, Creative Biolabs offers extremely useful and valuable biotechnological services for macrophage development projects. Our featured services include but are not limited to:
Creative Biolabs has built a highly experienced team of scientists and quality staff that have a long history in macrophage isolation and culture. Human monocytes, human alveolar, murine peritoneal cavity, murine bone marrow, murine lung, and murine adipose tissues are available for macrophage isolation and culture.
Creative Biolabs designs and develops a range of useful products to aid our customers' macrophage research in IBD.
You can browse below and click to learn more.
Cat.No | Product Name | Product Type |
---|---|---|
MTS-0922-JF10 | Human Macrophages, Alveolar | Human Macrophages |
MTS-0922-JF99 | Human M0 Macrophages, 1.5 x 10^6 | Human M0 Macrophages |
MTS-0922-JF52 | C57/129 Mouse Macrophages, Bone Marrow | C57/129 Mouse Macrophages |
MTS-0922-JF7 | Human M2 Macrophages, Peripheral Blood, 10 x 10^6 | Human M2 Macrophages |
MTS-1022-JF1 | B129 Mouse Bone Marrow Monocytes, 1 x 10^7 cells | Immune cells |
MTS-1022-JF10 | Human PB CD14+ Monocytes (Age: 23), 5 x 10^7 cells | Immune cells |
MTS-1022-JF5 | CD1 Mouse Bone Marrow Monocytes, 1 x 10^7 cells | Immune cells |
MTS-1123-HM11 | Monocyte To Macrophage Differentiation Associated Protein (MMA) ELISA Kit, Colorimetric | ELISA Kit |
MTS-1123-HM9 | Macrophage Expressed Gene 1 (MPEG1) ELISA Kit, Colorimetric | ELISA Kit |
MTS-1123-HM15 | Macrophage Chemokine Ligand 19 (CCL19) ELISA Kit, qPCR | ELISA Kit |
MTS-1123-HM50 | Macrophage Migration Inhibitory Factor (MIF) Competition ELISA Kit | ELISA Kit |
MTS-1122-YF49 | MacroCargo™ Human Monocyte-derived Macrophages (MDMs) with Chemo drugs (Nanoparticle System, Oligomannose-coated liposome) | MacroCargo |
MTS-1122-YF19 | MacroCargo™ Human PBMC-derived Macrophages with Chemo drugs (Nanoparticle System, PLGA) | MacroCargo |
MTS-1122-YF49 | MacroCargo™ Human Monocyte-derived Macrophages (MDMs) with Chemo drugs (Nanoparticle System, Oligomannose-coated liposome) | MacroCargo |
MTS-0124-LX2 | IFN-α Lentiviral Particle for Macrophage Engineering | Virus Particles |
MTS-0124-LX3 | IL-1β Lentiviral Particle for Macrophage Engineering | Virus Particles |
Copyright © 2025 Creative Biolabs. All Rights Reserved.